Cargando…
Comparing in vivo bioluminescence imaging and the Multi-Cruzi immunoassay platform to develop improved Chagas disease diagnostic procedures and biomarkers for monitoring parasitological cure
BACKGROUND: Chagas disease is caused by the protozoan parasite Trypanosoma cruzi and is a serious public health problem throughout Latin America. With 6 million people infected, there is a major international effort to develop new drugs. In the chronic phase of the disease, the parasite burden is ex...
Autores principales: | Francisco, Amanda Fortes, Saade, Ursula, Jayawardhana, Shiromani, Pottel, Hans, Scandale, Ivan, Chatelain, Eric, Liehl, Peter, Kelly, John M., Zrein, Maan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9560623/ https://www.ncbi.nlm.nih.gov/pubmed/36190992 http://dx.doi.org/10.1371/journal.pntd.0010827 |
Ejemplares similares
-
Development of a Novel Multiplex Immunoassay Multi-cruzi for the Serological Confirmation of Chagas Disease
por: Granjon, Elodie, et al.
Publicado: (2016) -
Limited Ability of Posaconazole To Cure both Acute and Chronic Trypanosoma cruzi Infections Revealed by Highly Sensitive In Vivo Imaging
por: Francisco, Amanda Fortes, et al.
Publicado: (2015) -
A novel high performing multiplex immunoassay Multi-HTLV for serological confirmation and typing of HTLV infections
por: Marqué, Lola, et al.
Publicado: (2021) -
Nitroheterocyclic drugs cure experimental Trypanosoma cruzi infections more effectively in the chronic stage than in the acute stage
por: Francisco, Amanda Fortes, et al.
Publicado: (2016) -
A novel assessment method for COVID-19 humoral immunity duration using serial measurements in naturally infected and vaccinated subjects
por: de Boer, Jasper, et al.
Publicado: (2022)